Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.

RW Jr, Frenck; CB, Creech; EA, Sheldon; DJ, Seiden; MK, Kankam; J, Baber; E, Zito; R, Hubler; J, Eiden; JM, Severs; S, Sebastian; J, Nanra; KU, Jansen; WC, Gruber; AS, Anderson; D, Girgenti

doi:10.1016/j.vaccine.2016.11.010

Public

Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.

Shared by NobleBlocks on Dec 1, 2016 • 12:00 AM UTC

Authors:

Frenck RW Jr

Creech CB

Sheldon EA

Abstract

<h4>Background</h4>A prophylactic Staphylococcus aureus four-antigen vaccine (SA4Ag) is under development for prevention of invasive S. aureus disease. A preliminary S. aureus three-antigen vaccine (SA3Ag) was reformulated to include a novel manganese transporter protein (MntC or rP305A). This study...

Subject

Staphylococcus aureus

Vaccine

Capsular polysaccharide

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!